More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$222224877
EPS
-1.28
P/E ratio
--
Price to sales
1.57
Dividend yield
--
Beta
1.203203
Previous close
$5.32
Today's open
$5.31
Day's range
$5.18 - $5.43
52 week range
$4.11 - $13.22
show more
CEO
Ron Kurtz
Employees
461
Headquarters
Aliso Viejo, CA
Exchange
NASDAQ Global Market
Shares outstanding
41929222
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
What RxSight (RXST) Said on Its Q3 Earnings Call
RxSight NASDAQ: RXST reported third-quarter revenue of $24.6 million, down 19% from $30.3 million a year earlier, as the company faced competitive pressure, seasonal effects and disruption tied to a commercial restructuring and sales-force expansion.
MarketBeat • Nov 4, 2026

RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript
RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

RxSight, Inc. Reports Third Quarter 2026 Results
ALISO VIEJO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended September 30, 2026.
GlobeNewsWire • Nov 3, 2026

RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.04 per share a year ago.
Zacks Investment Research • Nov 3, 2026

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight's common stock to two new non-executive officer employees in connection with the commencement of their employment with RxSight. RxSight also agreed to grant inducement restricted stock units (RSUs) covering a total of 637,449 shares of RxSight's common stock to the same employees in connection with the commencement of their employment with RxSight, which RSUs are anticipated to be granted on or about November 3, 2026.
GlobeNewsWire • Oct 24, 2026

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
GlobeNewsWire • Oct 20, 2026

RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy.
GlobeNewsWire • Oct 19, 2026

K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
K2 Vision has performed 5,000+ Light Adjustable Lens procedures and is recognized by RxSight as the highest-volume LAL practice in the world. Learn more.
GlobeNewsWire • Oct 16, 2026

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
GlobeNewsWire • Aug 26, 2026

RxSight Q2 Earnings Call Highlights
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
MarketBeat • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell RxSight Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.